ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Association between atorvastatin and sarcopenia: a study based on NHANES and FAERS databases.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Presynaptic compensation sustains neuromuscular transmission in the mouse diaphragm at a late stage of aging.Biogerontology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-marketing surveillance data suggest a potential link between atorvastatin use and sarcopenia. However, further large-scale observational studies are needed to confirm this preliminary finding. This study aims to comprehensively investigate the relationship between atorvastatin exposure and sarcopenia, with the goal of providing more accurate safety and efficacy profiles to guide its clinical use. We utilized two primary datasets: the National Health and Nutrition Examination Survey (NHANES) from 2011 to 2018 and the Food and Drug Administration Adverse Event Reporting System (FAERS) from 2004 to 2018. Using a multi-step analytical approach that included descriptive statistical analysis, multivariable logistic regression, and receiver operating characteristic (ROC) curve analysis, we systematically assessed the relationship between atorvastatin exposure and the incidence of sarcopenia. In the NHANES cohort analysis, after adjusting for demographic variables, lifestyle factors, and other confounders in the multivariable logistic regression model, atorvastatin use was associated with an increased risk of sarcopenia (OR = 2.21; 95% CI: 1.07-4.55; p = 0.032). An analysis of the FAERS database identified 13,625 adverse event reports related to atorvastatin, of which 5370 specifically documented myasthenia-related events. Independent analyses from both population-based epidemiological surveys and pharmacovigilance systems consistently indicate that atorvastatin use may increase the risk of sarcopenia. Based on these findings, we recommend that healthcare providers implement comprehensive risk communication strategies before prescribing atorvastatin, with particular emphasis on the need for regular musculoskeletal assessments in patients undergoing long-term statin therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.